Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the launches of Amgen's novel therapy AMG-531 and Ligand Pharmaceuticals/GlaxoSmithKline's SB-497115 will attain peak year sales of up to $1 billion and $500 million, respectively, for the treatment of thrombocytopenia, a major side effect of chemotherapy.

The new Pharmacor report entitled Managing the Side Effects of Chemotherapy focuses on the five major side effects of chemotherapy treatment: thrombocytopenia, chemotherapy-induced anemia, neutropenia, oral mucositis, and chemotherapy-induced nausea and vomiting. The report finds that the market for chemotherapy-related hematological toxicities (thrombocytopenia anemia, and neutropenia) was $6.3 billion in 2004 and will grow to $10.3 billion in 2014.

"Our findings indicate that the major players in the treatment of hematological toxicities -- Amgen, Johnson & Johnson, and Roche -- will continue to dominate the marketplace," said Mary Argent-Katwala, analyst at Decision Resources, Inc. "Additionally, we forecast that the launch of Amgen's AMG-531 and Ligand Pharmaceuticals/GlaxoSmithKline's SB-497115 will revolutionize the thrombocytopenia market as both companies are expected to implement education and marketing campaigns that we predict will produce an eightfold increase in drug-treatment rates for thrombocytopenia. Many of the physicians we surveyed indicated that thrombocytopenia is almost impossible to treat effectively using current methods."

About Thrombocytopenia

Thrombocytopenia is the reduction of the platelet (thrombocyte) count in the blood. This condition occurs when platelets are lost from circulation faster than the bone marrow can replace them.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc. ,

Many Choices for Medicare Prescription Drug Plans, Few Choices for Medicare Advantage Plans in Kansas and Missouri, According to HealthLeaders-Interstudy

View Now